Pembrolizumab (Keytruda®). HTA ID: 25066

Assessment Status NCPE Assessment Process Complete
HTA ID 25066
Drug Pembrolizumab
Brand Keytruda®
Indication Pembrolizumab as a monotherapy for the treatment of resectable, locally-advanced head and neck squamous cell carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without concomitant cisplatin and then as monotherapy in adults whose tumours express PD-L1 with a CPS ≥ 1.
Assessment Process
Rapid review commissioned 10/11/2025
Rapid review completed 09/12/2025
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab for this indication as an adjunct to the current standard of care.
Full HTA commissioned by the HSE 19/12/2025
Pre-submission consultation with Applicant 03/02/2026
Full submission received from Applicant 09/06/2026
Preliminary review sent to Applicant 16/07/2026
NCPE assessment re-commenced 14/08/2026
Factual accuracy sent to Applicant 09/10/2026
NCPE assessment re-commenced 15/10/2026
NCPE assessment completed 30/10/2026
NCPE assessment outcome The NCPE recommends that pembrolizumab, for the indication under assessment, be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Summary

Plain English Summary

*Next steps: The NCPE Assessment Report and recommendation and Patient Organisation submission, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health Pricing and Supply of Medical Goods Act 2013.

 

Further information on this process may be found here.

Please see the HSE Pricing and Reimbursement Tracker for any updates on the reimbursement status of this drug.

HSE Pricing and Reimbursement Tracker